metformin has been researched along with CKD-MBD in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Excerpt | Relevance | Reference |
---|---|---|
"Metformin-treated rats did not develop hyperphosphatemia or hypocalcemia and this prevented the development of vascular calcification and inhibited the progression toward high bone turnover disease." | 1.48 | Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. ( Brand, K; D'Haese, PC; De Broe, ME; De Maré, A; Gottwald-Hostalek, U; Kamel, S; Lalau, JD; Neven, E; Opdebeeck, B; Verhulst, A; Vervaet, B, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Neven, E | 1 |
Vervaet, B | 1 |
Brand, K | 1 |
Gottwald-Hostalek, U | 1 |
Opdebeeck, B | 1 |
De Maré, A | 1 |
Verhulst, A | 1 |
Lalau, JD | 1 |
Kamel, S | 1 |
De Broe, ME | 1 |
D'Haese, PC | 1 |
1 other study available for metformin and CKD-MBD
Article | Year |
---|---|
Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
Topics: Adenine; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Humans; | 2018 |